-- Taxotere(R) data in the neoadjuvant setting will also be presented:
Abst 79: "Evaluating the efficacy of capecitabine given concomitantly
or in sequence to epirubicin/cyclophosphamide >> docetaxel as neoadjuvant
treatment for primary breast cancer. First efficacy analysis of the GBG/AGO
intergroup-study "GeparQuattro" >>. von Minckwitz G, et al.
Sunday, December 16, 2007, 11:00 AM / General session 7, Exhibit Hall D
Prior to surgery, patients were treated with epirubicin and
cyclophosphamide followed by either Taxotere(R) alone
(100 mg/m squared), Taxotere(R) (75 mg/m squared) combined with
capecitabine (1800 mg/m squared), or Taxotere(R) (100mg/m2) followed
by capecitabine (1800mg/m2). The primary endpoint of the study is the
pathologic complete response at surgery.
-- Data from another investigational non-anthracycline Taxotere(R)-based
regimen will be presented from a study in patients with advanced HER2
positive breast cancer:
Abst 309: "Evaluation of trastuzumab, docetaxel and capecitabine as first- line therapy for HER2-positive locally advanced or metastatic breast cancer." Wardley A, et al.
Friday, December 14th, 2007 5:00-7:00 PM / Poster discussion session 3, Antibodies and Immunotherapy - Ballroom B
About Breast Cancer
Breast cancer is the most frequently diagnosed cancer in women. It is
the second-leading cause of cancer death in women after lung cancer, and
since 1990 is increasing predominantly in women 50 and over. It is the
first cause of cancer mortality in women of 40 to 59 years old. According
to the American Cancer Society, an estimated 200,000 women are diagnosed
with breast cancer and approximately 40,000 women die of the disease in the
United States every year. A woman is diagnosed with breast cancer in the
United States every three m
Copyright©2007 PR Newswire.
All rights reserved